AI Article Synopsis

  • The study examined the effect of weight loss from laparoscopic adjustable gastric banding (LAGB) on adipocyte fatty acid-binding protein (A-FABP) levels in severely obese women.
  • After a year, participants lost an average of 24.9 kg, improving metabolic parameters, but A-FABP levels remained stable overall.
  • In a closer examination of a subgroup, A-FABP levels peaked 3 months post-surgery, indicating that it might be a marker for weight loss changes rather than a stable marker for metabolic syndrome.

Article Abstract

Objective: Adipocyte fatty acid-binding protein (A-FABP) is a plasma biomarker recently associated with the metabolic syndrome. The aim of these studies was to investigate changes of A-FABP during profound weight loss induced by laparoscopic adjustable gastric banding (LAGB).

Methods And Procedures: In study one, 29 severely obese female subjects were examined before and 1 year after surgical treatment. A subgroup of 10 patients was investigated in 3-month intervals. Metabolic parameters were determined using standard methods, and A-FABP was detected using a commercially available enzyme-linked immunosorbent assay.

Results: Mean weight loss after 1 year was 24.9 kg (P < 0.001), mainly due to a decrease in fat mass. Metabolic parameters improved substantially. However, serum A-FABP remained stable. In study two, a subgroup of 10 patients was examined quarterly to determine the time course of A-FABP changes. Quarterly measurements of serum A-FABP were significantly higher than baseline levels with the highest A-FABP value after the first 3 months, where patients had highest weight loss.

Discussion: Our results in study one show that A-FABP serum levels are positively associated with body weight and fat mass. However, 1 year after pronounced weight loss A-FABP levels remained unchanged. In study two, time course analyses revealed maximum increase of serum A-FABP in parallel to highest weight loss, which allows to suppose that A-FABP is not only a biomarker of the metabolic syndrome in the steady state, but also a marker of weight changes in dynamic situations.

Download full-text PDF

Source
http://dx.doi.org/10.1038/oby.2008.273DOI Listing

Publication Analysis

Top Keywords

weight loss
16
metabolic syndrome
12
serum a-fabp
12
a-fabp
11
biomarker associated
8
associated metabolic
8
weight
8
subgroup patients
8
metabolic parameters
8
fat mass
8

Similar Publications

Background: Bariatric surgery is the most effective intervention for severe pediatric obesity, but a subset of youth experience suboptimal weight loss and/or recurrent weight gain. Early re-initiation of obesity pharmacotherapy postoperatively may improve outcomes, though this has not been evaluated in pediatric populations.

Methods: A retrospective cohort study at a tertiary care children's hospital evaluated the safety and efficacy of reintroducing obesity pharmacotherapy within six weeks after laparoscopic sleeve gastrectomy (LSG).

View Article and Find Full Text PDF

Background: To investigate the effectiveness of different bariatric metabolic surgeries in improving metabolic syndrome indicators in patients.

Methods: A retrospective analysis was conducted on obese patients who underwent laparoscopic sleeve gastrectomy (LSG), laparoscopic sleeve gastrectomy + jejunojejunal bypass (LSG + JJB), and laparoscopic Roux-en-Y gastric bypass (LRYGB). Patients were categorized into groups based on their surgical procedure: LSG (N = 199), LSG + JJB (N = 242), and LRYGB (N = 288).

View Article and Find Full Text PDF

Purpose: While treatment modalities for Maisonneuve fractures involving the proximal third of the fibula are established, no studies to date have reported outcomes associated with syndesmotic-only fixation of middle third fibular shaft fractures. The purpose of this study was to evaluate outcomes associated with syndesmotic-only fixation in the treatment of Maisonneuve fractures involving the middle third of the fibula.

Methods: A retrospective review was conducted on 257 cases of syndesmotic ankle instability with associated fibular fractures at a level 1 trauma center between 2013 and 2023.

View Article and Find Full Text PDF

Background: Implementation of semaglutide weight loss therapy has been challenging due to drug supply and cost, underscoring a need to identify those who derive the greatest absolute benefit.

Objectives: Allocation of semaglutide was modeled according to coronary artery calcium (CAC) among individuals without diabetes or established atherosclerotic cardiovascular disease (CVD).

Methods: In this analysis, 3,129 participants in the MESA (Multi-Ethnic Study of Atherosclerosis) without diabetes or clinical CVD met body mass index criteria for semaglutide and underwent CAC scoring on noncontrast cardiac computed tomography.

View Article and Find Full Text PDF

Background: Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy.

Objectives: This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced heart failure with reduced ejection fraction (HFrEF).

Methods: In this observational, retrospective analysis, a total of 344 patients with advanced HFrEF (age 58 ± 10 years, 85% male, 67% NYHA functional class III), underwent clinical and echocardiographic examination, body composition evaluation by skinfolds and dual-energy x-ray absorptiometry, circulating metabolite assessment, Minnesota Living with Heart Failure Questionnaire, and right heart catheterization.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!